«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2024 05

Page:

973-977

Research Field:

Publishing date:

Info

Title:

Advances in endocrine therapy in advanced prostate cancer

Author(s):

NIU Xiangnan; ZHANG Yangang

Department of Urology,Bethune Hospital,Shanxi Medical University,Shanxi Taiyuan 030032,China.

Keywords:

advanced prostate cancer; endocrine therapy; mechanism

PACS:

R737.25

DOI:

10.3969/j.issn.1672-4992.2024.05.033

Abstract:

Prostate cancer is the second most common malignant tumor in men worldwide,and it is also the second most common cause of cancer-related deaths in men.The introduction of prostate specific antigen(PSA) screening has led to the early diagnosis of prostate cancer,but there are still some patients diagnosed with or progressing to high-risk,locally advanced or metastatic disease.In these patients,the importance of androgen and androgen receptor (AR) in the progression of prostate cancer has been recognized.Therefore,reducing testosterone levels to castrate levels has always been the cornerstone of advanced prostate cancer treatment.In the past few decades,androgen deprivation therapy(ADT£© is still widely regarded as the standard treatment for advanced prostate cancer despite the problem of survival rates.This article reviews the current status and progress of endocrine therapy for patients with advanced prostate cancer.

References:

£Û1£ÝGLINA S,RIVERO MA,MORALES A,et al.Studies on prostatic cancer I.The effect of castration,of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate by charles huggins and clarence V.hodges £ÛJ£Ý.J Sex Med,2010,7(2 Pt 1):640-644.
£Û2£ÝHO S.Estrogens and anti-estrogens:Key mediators of prostate carcinogenesis and new therapeutic candidates £ÛJ£Ý.Journal of Cellular Biochemistry,2004,91(3):491-503.
£Û3£ÝWONG YN,FERRALDESCHI R,ATTARD G,et al.Evolution of androgen receptor targeted therapy for advanced prostate cancer £ÛJ£Ý.Nat Rev Clin Oncol,2014,11(6): 365-376.
£Û4£ÝATTARD G,REID AH,A'HERN R,et al.Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer £ÛJ£Ý.J Clin Oncol,2009,27(23): 3742-3748.

£Û5£ÝMOSTAGHEL EA,MARCK BT,PLYMATE SR,et al.Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants £ÛJ£Ý.Clin Cancer Res,2011,17(18):5913-5925.
£Û6£ÝNIU Y,CHANG TM,YEH S,et al.Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails £ÛJ£Ý.Oncogene,2010,29(25):3593-3604.
£Û7£ÝGON¢sALVES BF,DE CAMPOS SGP,G¦VES RM,et al.Dual action of high estradiol doses on MNU-induced prostate neoplasms in a rodent model with high serum testosterone:Protective effect and emergence of unstable epithelial microenvironment £ÛJ£Ý.Prostate,2017,77(9): 970-983.
£Û8£ÝTURO R,SMOLSKI M,ESLER R,et al.Diethylstilboestrol for the treatment of prostate cancer:past,present and future £ÛJ£Ý.Scand J Urol,2014,48(1): 4-14.
£Û9£ÝGRENADER T,PLOTKIN Y,GIPS M,et al.Diethylstilbestrol for the treatment of patients with castration-resistant prostate cancer: retrospective analysis of a single institution experience £ÛJ£Ý.Oncol Rep,2014,31(1):428-434.
£Û10£ÝMOORTHY HK,LAXMAN PRABHU GG,VENUGOPAL P.The resurgence of estrogens in the treatment of castration-resistant prostate cancer £ÛJ£Ý.Indian J Urol,2019,35(3):189-196.
£Û11£ÝSCHALLY AV,BLOCK NL,RICK FG.Discovery of LHRH and development of LHRH analogs for prostate cancer treatment £ÛJ£Ý.Prostate,2017,77(9):1036-1054.
£Û12£ÝKLUTH LA,SHARIAT SF,KRATZIK C,et al.The hypothalamic-pituitary-gonadal axis and prostate cancer:implications for androgen deprivation therapy £ÛJ£Ý.World J Urol,2014,32(3):669-676.
£Û13£ÝDELLIS A,PAPATSORIS A.Therapeutic outcomes of the LHRH antagonists £ÛJ£Ý.Expert Rev Pharmacoecon Outcomes Res,2017,17(5):481-488.
£Û14£ÝSLATER H.Phase 3 hero trial finds relugolix to be superior to leuprolide in prostate cancer £ÛJ£Ý.Oncology (Williston Park),2020,34(7):252.
£Û15£ÝCULIG Z.Targeting the androgen receptor in prostate cancer £ÛJ£Ý.Expert Opin Pharmacother,2014,15(10):1427-1437.
£Û16£ÝFIZAZI K,TRAN N,FEIN L,et al.Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised,double-blind,phase 3 trial £ÛJ£Ý.Lancet Oncol,2019,20(5):686-700.
£Û17£ÝJAMES ND,DE BONO JS,SPEARS MR,et al.Abiraterone for prostate cancer not previously treated with hormone therapy £ÛJ£Ý.N Engl J Med,2017,377(4):338-351.
£Û18£ÝKARANIKA S,KARANTANOS T,YIN J,et al.Novel anti-androgen receptor signaling agents: Understanding the mechanisms of resistance £ÛJ£Ý.Asian Journal of Urology,2014,1(1):30-39.
£Û19£ÝPLANTE M,LAPOINTE S,LABRIE F.Stimulatory effect of synthetic progestins currently used for the treatment of prostate cancer on growth of the androgen-sensitive Shionogi tumor in mice £ÛJ£Ý.J Steroid Biochem,1988,31(1):61-64.
£Û20£ÝDUPONT A,GOMEZ JL,CUSAN L,et al.Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy £ÛJ£Ý.J Urol,1993,150(3):908-913.
£Û21£ÝKAWATA H,ISHIKURA N,WATANABE M,et al.Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity £ÛJ£Ý.Prostate,2010,70(7):745-754.
£Û22£ÝKEAM SJ.Rezvilutamide:First approval £ÛJ£Ý.Drugs,2023,83(2):189-193.
£Û23£ÝGU W,HAN W,LUO H,et al.Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume,metastatic,hormone-sensitive prostate cancer (CHART):A randomised,open-label,phase 3 trial £ÛJ£Ý.Lancet Oncol,2022,23(10):1249-1260.
£Û24£ÝSEMENAS J,DIZEYI N,PERSSON JL.Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer £ÛJ£Ý.Drug Des Devel Ther,2013,7:875-881.
£Û25£ÝARMSTRONG AJ,SZMULEWITZ RZ,PETRYLAK DP,et al.ARCHES:A randomized,phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer £ÛJ£Ý.J Clin Oncol,2019,37(32):2974-2986.
£Û26£ÝDAVIS ID,MARTIN AJ,STOCKLER MR,et al.Enzalutamide with standard first-line therapy in metastatic prostate cancer£ÛJ£Ý.N Engl J Med,2019,381(2):121-131.
£Û27£ÝHUSSAIN M,FIZAZI K,SAAD F,et al.Enzalutamide in men with nonmetastatic,castration-resistant prostate cancer£ÛJ£Ý.N Engl J Med,2018,378(26):2465-2474.
£Û28£ÝCLEGG NJ,WONGVIPAT J,JOSEPH JD,et al.ARN-509:A novel antiandrogen for prostate cancer treatment £ÛJ£Ý.Cancer Res,2012,72(6):1494-1503.
£Û29£ÝCHI KN,AGARWAL N,BJARTELL A,et al.Apalutamide for metastatic, castration-sensitive prostate cancer £ÛJ£Ý.N Engl J Med,2019,381(1):13-24.
£Û30£ÝRATHKOPF DE,ANTONARAKIS ES,SHORE ND,et al.Safety and antitumor activity of apalutamide (ARN-509) in metastatic castration-resistant prostate cancer with and without prior abiraterone acetate and prednisone £ÛJ£Ý.Clin Cancer Res,2017,23(14):3544-3551.
£Û31£ÝCRAWFORD ED,SCHELLHAMMER PF,MCLEOD DG,et al.Androgen receptor targeted treatments of prostate cancer:35 years of progress with antiandrogens£ÛJ£Ý.J Urol,2018,200(5):956-966.
£Û32£ÝFIZAZI K,SHORE N,TAMMELA TL,et al.Darolutamide in nonmetastatic,castration-resistant prostate cancer £ÛJ£Ý.N Engl J Med,2019,380(13):1235-1246.
£Û33£ÝHUSSAIN M,TOMBAL B,SAAD F,et al.Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase ¢ó ARASENS trial £ÛJ£Ý.Journal of Clinical Oncology,2023,41(20):3595-3607.
£Û34£ÝMORI K,MOSTAFAEI H,PRADERE B,et al.Apalutamide,enzalutamide,and darolutamide for non-metastatic castration-resistant prostate cancer:A systematic review and network meta-analysis £ÛJ£Ý.Int J Clin Oncol,2020,25(11):1892-1900.
£Û35£ÝWENZEL M,NOCERA L,COLL¨¤RUVOLO C,et al.Overall survival and adverse events after treatment with darolutamide vs apalutamide vs enzalutamide for high-risk non-metastatic castration-resistant prostate cancer:A systematic review and network meta-analysis £ÛJ£Ý.Prostate Cancer and Prostatic Diseases,2021,25(2):139-148.
£Û36£ÝWATSON PA,ARORA VK,SAWYERS CL.Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer £ÛJ£Ý.Nat Rev Cancer,2015,15(12):701-711.
£Û37£ÝSIEGEL RL,MILLER KD,JEMAL A.Cancer statistics,2019 £ÛJ£Ý.CA Cancer J Clin,2019,69(1):7-34.
£Û38£ÝCHEN XQ,HUANG Y,LI X,et al.Efficacy of maximal androgen blockade versus castration alone in the treatment of advanced prostate cancer:a retrospective clinical experience from a Chinese medical centre £ÛJ£Ý.Asian J Androl,2010,12(5): 718-727.
£Û39£ÝPERERA M,ROBERTS MJ,KLOTZ L,et al.Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer £ÛJ£Ý.Nature Reviews Urology,2020,17(8):469-481.
£Û40£ÝBONFILL X,AREVALO-RODRIGUEZ I,GARCIA LM,et al.Intermittent androgen deprivation therapy:recommendations to improve the management of patients with prostate cancer following the GRADE approach £ÛJ£Ý.Cancer Management and Research,2018,10:2357-2367.
£Û41£ÝCHUN-LEUNG CHAU D,WANG D,TEDESCO A,et al.Prostate cancer patients' preferences for intermittent vs continuous androgen deprivation-A pilot institutional study £ÛJ£Ý.J Med Imaging Radiat Sci,2016,47(1):108-112,e102.
£Û42£ÝKLOTZ L,HIGANO CS.Intermittent androgen deprivation therapy-an important treatment option for prostate cancer£ÛJ£Ý.JAMA Oncol,2016,2(12):1531-1532.
£Û43£ÝMOHILE SG,MUSTIAN K,BYLOW K,et al.Management of complications of androgen deprivation therapy in the older man £ÛJ£Ý.Crit Rev Oncol Hematol,2009,70(3):235-255.

Memo

Memo:

-

Common functions

Last Update: 2024-01-30